Combined Treatment with Low Concentrations of Decitabine and SAHA Causes Cell Death in Leukemic Cell Lines but Not in Normal Peripheral Blood Lymphocytes

Replicatively senescent cells are arrested in G1 and G2 phases

(2016) Zhiyong Mao et al.   Aging-US

Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer

(2013) Liqin Xu et al.   ANTI-CANCER DRUGS

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

(2013) Holger Gerullis et al.   ANTI-CANCER DRUGS

The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice

(2013) Hiroshi Aketa et al.   INTERNATIONAL JOURNAL OF CANCER

Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer

(2013) M. S. Lee et al.   ONCOLOGIST

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

(2012) P. Yan et al.   BLOOD

Regulation of Bax mitochondrial localization by Bcl-2 and Bcl-xL: Keep your friends close but your enemies closer

(2012) Thibaud T. Renault et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Reactive Oxygen Species and Mitochondrial Sensitivity to Oxidative Stress Determine Induction of Cancer Cell Death by p21

(2012) Ionica Masgras et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Decitabine and Vorinostat Cooperate To Sensitize Colon Carcinoma Cells to Fas Ligand-Induced Apoptosis In Vitro and Tumor Suppression In Vivo

(2012) D. Yang et al.   JOURNAL OF IMMUNOLOGY

Highly Synergistic Effect of Sequential Treatment with Epigenetic and Anticancer Drugs To Overcome Drug Resistance in Breast Cancer Cells Is Mediated via Activation of p21 Gene Expression Leading to G2/M Cycle Arrest

(2012) Sivakumar Vijayaraghavalu et al.   MOLECULAR PHARMACEUTICS

Combinatorial drug therapy for cancer in the post-genomic era

(2012) Bissan Al-Lazikani et al.   NATURE BIOTECHNOLOGY

Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening

(2012) Matthew A. Held et al.   Cancer Discovery

Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells

(2011) Qiong Zhou et al.   BMC NEUROSCIENCE

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy

(2011) Min-Yu Chen et al.   CANCER

Epigenetic aberrations during oncogenesis

(2011) Maria Hatziapostolou et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage

(2011) Haiying Wang et al.   DNA REPAIR

Generation of Reactive Oxygen Species during Apoptosis Induced by DNA-Damaging Agents and/or Histone Deacetylase Inhibitors

(2011) Barbora Brodská et al.   Oxidative Medicine and Cellular Longevity

Structure and Function of Mammalian DNA Methyltransferases

(2010) Renata Zofia Jurkowska et al.   CHEMBIOCHEM

Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma

(2010) S. Amatori et al.   LUNG CANCER

Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA

(2010) Barbora Brodská et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Feedback between p21 and reactive oxygen production is necessary for cell senescence

(2010) João F Passos et al.   Molecular Systems Biology

Epigenetics in cancer

(2009) S. Sharma et al.   CARCINOGENESIS

Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery

(2009) A. Ganesan et al.   CURRENT CANCER DRUG TARGETS

p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions

(2009) Hirohito Yamaguchi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

(2008) P. A. Link et al.   CANCER RESEARCH

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL

Free radicals and senescence

(2008) Teng Lu et al.   EXPERIMENTAL CELL RESEARCH

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

(2008) Carlo Stresemann et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

(2008) Q. Zhou et al.   MOLECULAR CANCER RESEARCH